New England Journal of Medicine: February 26, 2026 – Volume 394, Issue 9

The landscape of HIV treatment saw a significant development this month with the publication of results from the STOMP trial in the New England Journal of Medicine. The study, detailed in the February 26, 2026 issue (Volume 394, Issue 9), offers a new approach to managing the virus, particularly for individuals who have difficulty adhering to daily medication regimens. This is a crucial area of focus, as consistent adherence is vital for suppressing viral load and preventing transmission. The findings, initially announced in late 2025, are now available with full data and analysis, prompting discussion among clinicians and advocates about how best to integrate this option into patient care.

Long-Acting Injectable Therapy: A New Option for HIV Management

The STOMP (Study to Monitor the Efficacy and Safety of Dolutegravir and Cabotegravir Administered as Long-Acting Injectable Therapy) trial investigated the use of cabotegravir and rilpivirine, administered as intramuscular injections, as an alternative to daily oral antiretroviral therapy. Currently, the standard of care for HIV involves taking a pill, or combination of pills, every day. While highly effective, this can present challenges for some individuals, including remembering to take medication, potential side effects and concerns about stigma associated with daily treatment. Long-acting injectable therapy aims to address these challenges by reducing the frequency of medication administration.

The trial, conducted by the ACTG (AIDS Clinical Trials Group), enrolled adults living with HIV who had a viral load suppressed on oral antiretroviral therapy. Participants were randomly assigned to either continue their oral regimen or switch to the injectable regimen, receiving injections once every two months. The primary endpoint of the study was to assess whether the injectable regimen was non-inferior to the oral regimen in maintaining viral suppression. As reported by The Manila Times, the results demonstrated that the injectable regimen was indeed non-inferior, meaning it performed at least as well as the oral regimen in maintaining viral suppression.

Understanding the Trial’s Design and Limitations

The STOMP trial was a randomized, controlled, non-inferiority trial. This means participants were randomly assigned to one of two groups – the injectable group or the oral group – and the researchers aimed to show that the injectable regimen was not worse than the oral regimen. It’s important to note that non-inferiority does not necessarily mean the injectable regimen is *better* than the oral regimen, only that it is comparable in effectiveness.

The study did have some limitations. Participants were required to have a suppressed viral load before entering the trial, meaning the results do not apply to individuals who are newly diagnosed or have not yet achieved viral suppression. The trial excluded individuals with certain medical conditions or those taking certain medications. The long-term safety and efficacy of the injectable regimen also remain to be fully established, requiring ongoing monitoring and follow-up.

What This Means for People Living with HIV

The approval of long-acting injectable therapy represents a significant step forward in HIV treatment. For individuals who struggle with daily pill adherence, this new option could offer a more convenient and discreet way to manage their condition. Reducing the burden of daily medication can improve quality of life and potentially reduce the risk of viral rebound due to missed doses. However, it’s crucial to remember that this is not a one-size-fits-all solution.

The decision to switch to injectable therapy should be made in consultation with a qualified healthcare provider, taking into account individual circumstances, medical history, and preferences. It’s also important to be aware of potential side effects, which may include injection site reactions. The Centers for Disease Control and Prevention (CDC) provides comprehensive information on HIV treatment options and adherence strategies.

Risk Context and the Importance of Continued Surveillance

While long-acting injectables offer a new avenue for treatment, it’s vital to maintain perspective on the overall context of HIV risk. Globally, millions of people are still living with HIV, and access to treatment remains a significant challenge in many regions. The development of new treatment options like this is crucial, but it must be coupled with efforts to expand access to testing, prevention, and care.

Continued surveillance of viral resistance patterns is also essential. As with any antiretroviral therapy, there is a risk that the virus could develop resistance to the medications used in the injectable regimen. Ongoing monitoring and research are needed to track resistance trends and inform treatment guidelines.

The Evolving Landscape of HIV Treatment: What Comes Next

The publication of the STOMP trial results is likely to prompt updates to HIV treatment guidelines from organizations such as the World Health Organization (WHO) and the U.S. Department of Health and Human Services. These guidelines provide recommendations to healthcare providers on the optimal management of HIV infection.

Further research is also underway to explore the potential of long-acting injectable therapy in other populations, including individuals who are newly diagnosed with HIV. Studies are also investigating the use of other long-acting antiretroviral medications, with the goal of developing even more convenient and effective treatment options. The ongoing commitment to research and innovation is essential for ultimately achieving the goal of ending the HIV epidemic.